胃癌多学科诊断和治疗模式

Phase Ⅲ trial of adjuvant capecitabine/cisplatin (XP) compared with capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial):Safety analysis 2010

Hartgrink HH.van de Velde CJ.Putter H Neo-adjuvant chemotherapy for operable gastric cancer:long term results of the Dutch randomised FAMTX trial 2004(6)

张军.张菁.孟化.吴国聪.蔡军.王康里.张忠涛.王宇 改良FOLFOX7方案新辅助化疗对进展期胃癌患者的疗效分析 2009(6)

Persiani R.Rausei S.Pozzo C 7-Year survival results of perioperative chemotherapy with epidoxorubicin,etoposide,and cisplatin (EEP) in locally advanc5d resectable gastric cancer:upto-date analysis of a phase-Ⅱ study 2008(8)

Yoshikawa T.Sasako M.Yamamoto S Phase Ⅱ study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer 2009(9)

Ott K.Sendler A.Becker K Neoadjuvant chemotherapy with cisplatin,5-FU,and leucovorin(PLF)in locally advanced gastric cancer:a prospective phase Ⅱ study 2003(3)

>>更多...

Multidisciplinary management of gastric cancer

The therapeutic mode has changed over time, although surgery remains the main treatment of choice for gastric cancer. Surgery alone provides long-term survival in only 30% of patients with advanced stages because of the high risk of recurrence and metastasis. Multimodal strategies including neoadjuvant and (or) adjuvant protocols combined with surgery have significantly improved the prognosis of patients with gastric cancer. In particular, perioperative chemotherapy has become the new standard for treatment of patients with advanced gastric cancer. Adjuvant therapy should be carefully discussed after surgical resection, mainly in patients with large lymph node-positive tumors when neoadjuvant therapy can not be carried out. This article reviews the relevant literature on the multidisciplinary management of gastric cancer, and discusses strategies to improve the efficacy of locoregional failures.